An application has been filed in Quebec to obtain authorization
to institute a class action concerning the drugs Mounjaro,
Trulicity, and Zepbound, alleging that the widely used diabetes and
weight-loss medications may expose patients to serious health risks
that were not adequately disclosed. On December 23, 2025, Siskinds
LLP's Quebec affiliate, Siskinds Desmeules, applied to the
Superior Court of Quebec for authorization to bring a case on
behalf of Quebec residents who were prescribed and used GLP-1
receptor agonists and experienced serious health problems.
The lawsuit targets Eli Lilly and Company and its Canadian
subsidiary, alleging their liability as manufacturers and for other
breaches, arguing that they failed to properly warn patients and
healthcare providers about serious known or foreseeable risks posed
by the active ingredients in the drugs, dulaglutide and
tirzepatide. According to the claim, the drugs were marketed as
safe and effective without